FOLH1 and neoplasm: [177Lu]Lu-DOTA-(2P-PEG4)2 showed better imaging capacity than [177Lu]Lu-PSMA-617 (Figure 6G), and the in vivo tumor uptake was still obvious at 48 h after injection (Figure 6F), indicating that it possessed a longer detention time in vivo and a sound tumor-targeting ability.